Supplementary Figure 7: Loss of ALOX12 has no effect on Erastin- or RSL-3 -induced ferroptosis.
From: ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway
(a) WT, ALOX12+/−, ALOX12−/− MEFs were treated with different concentrations of Erastin (1, 2.5, 5 and 10 uM) for 12 h. Quantification of cell death is shown. Error bars are mean ± s.d., n = 3 independent experiments. (b) U2OS control or ALOX12 crispr cells, were treated with Erastin (20 uM) and Ferr-1 (2 uM) as indicated for 12 h. Quantification of cell death is shown. Error bars are mean ± s.d., n = 3 independent experiments. (c) Representative phase-contrast images of U2OS control or ALOX12 crispr cells treated with RSL-3 (4 uM) and Ferr-1 (2 uM) as indicated for 12h (Scale bars, 100 µm). The experiments were repeated three times, independently, with similar results. (d) U2OS control or ALOX12 crispr cells treated with RSL-3 (4 uM) and Ferr-1 (2 uM as indicated for 12 h. Quantification of cell death is shown. Error bars are mean ± s.d., n = 3 independent experiments. All P values (a,b,d) were calculated using two-tailed unpaired Student’s t-test. Raw data are provided in Supplementary Table 1
